培唑帕尼联合化疗治疗晚期滑膜肉瘤的近期疗效及安全性  

Short-Term Efficacy and Safety of Pazopanib Combined with Chemotherapy in Treatment of Advanced Synovial Sarcoma

作　　者：王晶 林峰 WANG Jing;LIN Feng(Department of Tumor,Shanghai Eighth People’s Hospital,Shanghai 200235,China)

机构地区：[1]上海市第八人民医院肿瘤科,上海200235

出　　处：《肿瘤防治研究》2025年第4期313-318,共6页Cancer Research on Prevention and Treatment

摘　　要：目的探讨培唑帕尼联合化疗治疗晚期滑膜肉瘤(SS)的近期疗效及安全性。方法回顾性分析接受培唑帕尼联合不同化疗方案治疗的晚期滑膜肉瘤患者64例,其中,采取一线化疗方案26例、二线化疗方案19例、三线化疗方案19例,对不同方案的治疗效果和安全性进行评价。结果64例患者中,33例患者部分缓解,12例患者疾病稳定,19例患者疾病进展,其客观缓解率(ORR)和疾病控制率(DCR)分别为51.6%(33/64)和70.3%(45/64),中位PFS为7.55个月(95%CI:6.320~8.780)。采用一线化疗方案的26例患者ORR为65.4%(17/26),DCR为73.1%(19/26),中位PFS为9.167个月(95%CI:6.362~11.971);采用二线化疗方案的19例患者ORR为47.4%(9/19),DCR为73.7%(14/19),中位PFS为7.55月(95%CI:6.054~9.046);三线化疗方案的19例患者ORR为36.8%(7/19),DCR为63.2%(12/19),中位PFS为6.09月(95%CI:3.158~9.022)。不良反应以Ⅰ/Ⅱ级为主,Ⅲ/Ⅳ级不良事件很少出现,治疗过程中没有死亡案例。结论培唑帕尼联合化疗治疗晚期滑膜肉瘤的疗效较好,不良反应可以接受。Objective To investigate the short-term efficacy and safety of pazopanib combined with chemotherapy in the treatment of advanced synovial sarcoma(SS).Methods A total of 64 patients with advanced SS treated with pazopanib combined with different chemotherapy regimens were selected.Among them,26 patients received first-line chemotherapy regimen,19 patients received second-line chemotherapy regimen,and 19 patients received third-line chemotherapy regimen.The therapeutic efficacy and safety of different treatment regimens were evaluated.Results Out of the 64 patients,33 achieved partial response(PR),12 had stable disease(SD),and 19 experienced progression disease(PD).The objective response rate(ORR)and disease control rate(DCR)were 51.6%(33/64)and 70.3%(45/64),respectively,with a median progression-free survival(PFS)of 7.55 months(95%CI:6.320–8.780 months).Among the 26 patients treated with the first-line chemotherapy regimen,the ORR was 65.4%(17/26),the DCR was 73.1%(19/26),and the median PFS was 9.167 months(95%CI:6.362–11.971 months).For the 19 patients receiving second-line chemotherapy regimen,the ORR was 47.4%(9/19),the DCR was 73.7%(14/19),and the median PFS was 7.55 months(95%CI:6.054–9.046 months).Among the 19 patients treated with the third-line chemotherapy regimen,the ORR was 36.8%(7/19),the DCR was 63.2%(12/19),and the median PFS was 6.09 months(95%CI:3.158–9.022 months).The majority of adverse events were gradeⅠ/Ⅱ,whereas gradeⅢ/Ⅳadverse events rarely occurred.No deaths occurred during the course of treatment.Conclusion Pazopanib combined with chemotherapy shows good efficacy in the treatment of advanced SS,with acceptable adverse events.

关 键 词：滑膜肉瘤 培唑帕尼 分子靶向治疗 化疗 

分 类 号：R738.5[医药卫生—肿瘤]